ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
March 19 2024 - 8:30AM
via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC)
("Company"), a clinical-stage biopharmaceutical company developing
therapeutic solutions in oncology/hematology, CNS, and
ophthalmology, proudly announced today that its CEO, Dr. Uttam
Patil, was selected as one of the Top 10 CEOs in Taiwan 2024
by CEO Insights Asia Magazine. This recognition is a testament
to Dr. Patil's outstanding leadership, innovative vision, and
significant contributions to the Company. Dr. Patil is confident in
the Company's prospects, so he owns stock options without claiming
a salary. Within his first year as the Company's CEO, the Company
saw a rise in the stock price of its common stock, an increase in
its social media presence, and a renewed focus on its essential
products.
Under Dr. Patil's leadership, ABVC's team has achieved
remarkable international growth and success. In November of last
year, ABVC received a patent for ADHD treatment; last month, they
received a patent for their MDD solution in Australia. CEO Insights
Asia writes that Dr. Patil, "a unique amalgamation of scholarly
acumen and practical insight fuels a forward-thinking approach,
steering companies toward sustained success and pioneering
innovation (CEO Insight Asia 19)". The magazine celebrates leaders
with exceptional leadership, strategic thinking, and a commitment
to driving positive change within their organizations and the
industry. This award is a well-deserved honor for Dr. Patil and
reflects his dedication to excellence.
Dr. Patil believes in a clear mission beyond
profit-making and wants the Company to positively impact society
through innovative products, sustainable practices, and community
engagement. He emphasizes innovation as a core driver of growth.
While pursuing growth and innovation, Dr. Patil strives to focus
equally on financial discipline and stability, which he believes
creates long-term value for shareholders.His team is passionate
about delivering exceptional value to society and continues to
prioritize understanding society's needs, preferences, and pain
points. Dr. Patil recognizes that the Company's success hinges on
its people as they aspire to cultivate a vibrant, inclusive, and
high-performing culture where employees are empowered, motivated,
and given opportunities to thrive and develop their skills.
To read the complete story and learn about Dr.
Uttam Patil's views,
visit https://www.ceoinsightsasia.com/digital-magazine/ceos-in-taiwan-march-2024/#page=24
For more information about ABVC and its
subsidiaries, stay updated on the latest updates or
visit https://abvcpharma.com.
ABVC urges its shareholders to sign up on the
Company's website for the latest news alerts;
visit https://abvcpharma.com/?page_id=17707
About ABVC BioPharmaABVC BioPharma is a
clinical-stage biopharmaceutical company with an active pipeline of
six drugs and one medical device (ABV-1701/Vitargus®) under
development. For its drug products, the Company utilizes
in-licensed technology from its network of world-renowned research
institutions to conduct proof-of-concept trials through Phase II of
clinical development. The Company's network of research
institutions includes Stanford University, University of California
at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®,
the Company intends to conduct global clinical trials through Phase
III.
Forward-Looking StatementsThis press
release contains "forward-looking statements." Such statements may
be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates,"
"aims," "believes," "hopes," "potential," or similar words.
Forward-looking statements are not guarantees of future
performance, are based on certain assumptions, and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company's control, and cannot be predicted or
quantified, and, consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
None of the outcomes expressed herein are guaranteed. Such risks
and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to proceed to the next level of the clinical
trials or to market our product candidates. More detailed
information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the
Company's filings with the Securities and Exchange Commission
(SEC), including the Company's Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors are urged to read these
documents free of charge on the SEC's website
at http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Contact:Leeds
ChowEmail: leedschow@ambrivis.com
ABVC BioPharma (NASDAQ:ABVC)
Historical Stock Chart
From Jul 2024 to Aug 2024
ABVC BioPharma (NASDAQ:ABVC)
Historical Stock Chart
From Aug 2023 to Aug 2024